insiderwall
Menu
SuperinvestorInsider
Maze Therapeutics Inc. MAZE

Super Investor & Insider

Nessuna transazione insider negli ultimi 6 mesi.

Fondi: 13F-HR alla SEC. Insider: acquisti (P) e vendite (S) in borsa da SEC EDGAR, ultimi 12 mesi.

About

Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity. The company harnesses human genetics through its Compass platform to identify genetic variants in diseases and link them to biological pa

SectorHealthcare
ExchangeNASDAQ
IndustryBiotechnology
CountryUnited States
Employees141
TickerMAZE

Statistics

Market Cap$1.24B
Revenue (TTM)$19.1M
Net Income-$131.1M
Net Margin-687.0%
EPS$-3.05
P/E189.50
P/S64.81
P/B3.38
EV/EBITDA-7.83
ROE-38.7%
Dividend Yield
Price$24.87

Data: Twelve Data · Revenue = mcap / P/S